BIVINASDAQHealthcare · Biotechnology

BioVie Inc.

$1.35+3.05%(+$0.04)

TickerSpark Score

59/100

Mixed

100

Valuation

Profitability

Growth

Health

Momentum

Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BIVI research report →

52-Week Range3% of range

Low $1.06

Current $1.35

High $12.10

Companybioviepharma.com

BioVie Inc. , a clinical stage biotechnology company, engages in the discovery, development, and commercialization of drugs therapies in the United States. Its products in pipeline include BIV201, which completed Phase IIa clinical trial for the treatment of ascites due to chronic liver cirrhosis; and NE3107, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease and Phase I clinical trial for the treatment of Parkinson's disease.

CEO: Cuong Viet Do
IPO: 2020
Employees: 14
HQ: Carson City, NV, US

Price Chart

-87.02% · this period

Valuation

Market Cap: $10.18M
P/E: -0.51
P/S: 0.00
P/B: 0.65
EV/EBITDA: 0.13
Div Yield: 0.00%

Profitability

Gross Margin: 0.00%
Op Margin: 0.00%
Net Margin: 0.00%
ROE: -101.09%
ROIC: -129.50%

Growth & Income

Revenue: $0 · 0.00%
Net Income: $-17,542,120 · 45.39%
EPS: $-12.12 · 83.41%
Op Income: $-18,066,200
FCF YoY: 31.92%

Performance & Tape

52W High: $12.10
52W Low: $1.06
50D MA: $1.45
200D MA: $1.57
Beta: 0.72
Avg Volume: 79.33K

Get TickerSpark's AI analysis on BIVI

Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.

Get Pro Access →

30-day money-back guarantee · cancel anytime

Recent Insider Transactions

Date	Insider	Role	Type	Shares	Value
Jan 5, 26	Palumbo Joseph M	officer: Chief Medical Officer	other	132,000	$172.92K
Jan 5, 26	KIM JOANNE WENDY	officer: Chief Financial Officer	other	110,100	$144.23K
Jan 5, 26	ROGICH SIGMUND	director	other	141,100	$184.84K
Jan 5, 26	ROGICH SIGMUND	director	other	70,000	$91.70K
Jan 5, 26	DO CUONG V	director, officer: President & CEO	other	665,300	$871.54K
Jan 5, 26	Sherman Michael Edward	director	other	341,100	$446.84K
Jan 5, 26	Sherman Michael Edward	director	other	80,000	$104.80K
Jan 5, 26	Farag Kameel D.	director	other	57,500	$75.33K
Jan 5, 26	Chappell Amy Suzon	director	other	57,500	$75.33K
Jan 5, 26	Lang James Paul	director	other	330,500	$432.95K

Our BIVI Coverage

We haven't published any research on BIVI yet

For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.

Generate BIVI Report →